PMID- 34992382
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220108
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 14
DP  - 2021
TI  - Clinical Impact of Switching to Ceritinib After Severe AEs Related to 
      Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case 
      Report.
PG  - 5471-5475
LID - 10.2147/OTT.S340984 [doi]
AB  - Lung cancer is still the leading cause of morbidity and mortality by cancer among 
      men, according to the latest epidemiological data in China. Anaplastic lymphoma 
      kinase (ALK) rearrangements act as key oncogenic drivers of non-small cell lung 
      cancer (NSCLC) and have been identified in 5-6% of NSCLC. Although ALK inhibitors 
      (ALK-TKIs) were proven to be more effective than chemotherapy in ALK-positive 
      NSCLC patients and the safety profile of these drugs was favorable, novel ALK 
      fusions NSCLC might discontinue or switch treatment because of adverse events 
      (AEs) have rarely previously been reported. Here, we describe a male patient with 
      stage IV lung adenocarcinoma who carried a novel PTH2R-ALK fusion identified by 
      next-generation sequencing (NGS). The patient first took crizotinib but switched 
      to alectinib due to gastrointestinal AEs. Although alectinib remained effective 
      on tumors, ceritinib (450 mg) was replaced after the AEs of hyperbilirubinemia 
      occurred. After reducing the dose to 300mg, the diarrhea AEs caused by ceritinib 
      were effectively relieved, and the patient obtained sustained clinical benefit 
      with progression-free survival nearly 12 months. Our findings offer valuable 
      information for the safety management of NSCLC patients with a novel PTH2R-ALK 
      fusion treated by ALK-TKIs.
CI  - (c) 2021 Shen et al.
FAU - Shen, Gang
AU  - Shen G
AD  - Department of Radiology, The Affiliated Kunshan Hospital of Jiangsu University, 
      Kunshan, People's Republic of China.
FAU - Du, Yinping
AU  - Du Y
AD  - Department of Radiology, The Affiliated Kunshan Hospital of Jiangsu University, 
      Kunshan, People's Republic of China.
FAU - Shen, Jifang
AU  - Shen J
AD  - Department of Radiology, The Affiliated Kunshan Hospital of Jiangsu University, 
      Kunshan, People's Republic of China.
FAU - Zhang, Junling
AU  - Zhang J
AUID- ORCID: 0000-0003-3518-7584
AD  - The Medical Department, 3D Medicines, Inc., Shanghai, People's Republic of China.
FAU - Xia, Xihua
AU  - Xia X
AD  - The Medical Department, 3D Medicines, Inc., Shanghai, People's Republic of China.
FAU - Huang, Mengli
AU  - Huang M
AUID- ORCID: 0000-0003-0169-7906
AD  - The Medical Department, 3D Medicines, Inc., Shanghai, People's Republic of China.
FAU - Shen, Wenxiang
AU  - Shen W
AD  - Department of Oncology, The Affiliated Kunshan Hospital of Jiangsu University, 
      Kunshan, People's Republic of China.
LA  - eng
PT  - Case Reports
DEP - 20211223
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC8711735
OTO - NOTNLM
OT  - PTH2R-ALK
OT  - adverse events
OT  - ceritinib
OT  - non-small cell lung cancer
COIS- Junling Zhang, Xihua Xia, and Mengli Huang were employed by the company Shanghai 
      3D Medicines Inc. The authors declared no other conflicts of interest.
EDAT- 2022/01/08 06:00
MHDA- 2022/01/08 06:01
PMCR- 2021/12/23
CRDT- 2022/01/07 06:20
PHST- 2021/09/24 00:00 [received]
PHST- 2021/12/09 00:00 [accepted]
PHST- 2022/01/07 06:20 [entrez]
PHST- 2022/01/08 06:00 [pubmed]
PHST- 2022/01/08 06:01 [medline]
PHST- 2021/12/23 00:00 [pmc-release]
AID - 340984 [pii]
AID - 10.2147/OTT.S340984 [doi]
PST - epublish
SO  - Onco Targets Ther. 2021 Dec 23;14:5471-5475. doi: 10.2147/OTT.S340984. 
      eCollection 2021.